Reyon Pharmaceutical Co Ltd (102460) — Cash Flow Quality Index
Reyon Pharmaceutical Co Ltd (102460) has a Cash Flow Quality Index of 11.17x as of March 2025. Operating cash flow of ₩2.41 Billion exceeds net income of ₩216.09 Million, indicating high earnings quality where cash backs reported profits. Explore investment intensity of Reyon Pharmaceutical Co Ltd to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Reyon Pharmaceutical Co Ltd Cash Flow Quality Index (2008–2024)
Historical Cash Flow Quality Index for Reyon Pharmaceutical Co Ltd across 13 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Reyon Pharmaceutical Co Ltd (102460) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Reyon Pharmaceutical Co Ltd (2008–2024)
Year-by-year earnings quality comparison for Reyon Pharmaceutical Co Ltd. For live market cap and the full company financial profile, see 102460 company net worth.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | -0.35x | ₩-1.44 Billion | ₩4.15 Billion | ▼ -114.3% |
| 2023 | 2.41x | ₩8.65 Billion | ₩3.58 Billion | ▲ +105.5% |
| 2022 | 1.17x | ₩8.73 Billion | ₩7.43 Billion | ▼ -44.4% |
| 2021 | 2.11x | ₩11.68 Billion | ₩5.54 Billion | ▲ +76.4% |
| 2020 | 1.20x | ₩4.60 Billion | ₩3.84 Billion | ▲ +158.3% |
| 2019 | -2.05x | ₩-12.18 Billion | ₩5.94 Billion | ▼ -124.1% |
| 2018 | 8.53x | ₩11.45 Billion | ₩1.34 Billion | ▲ +555.4% |
| 2017 | 1.30x | ₩16.76 Billion | ₩12.89 Billion | ▲ +47.0% |
| 2016 | 0.89x | ₩9.47 Billion | ₩10.70 Billion | ▼ -39.0% |
| 2012 | 1.45x | ₩24.65 Billion | ₩16.99 Billion | ▲ +87.0% |
| 2011 | 0.78x | ₩15.34 Billion | ₩19.78 Billion | ▲ +45.5% |
| 2009 | 0.53x | ₩8.68 Billion | ₩16.29 Billion | ▼ -30.2% |
| 2008 | 0.76x | ₩5.99 Billion | ₩7.84 Billion | — |